SCHEMBL658207

SCHEMBL658207

O=C(/C=C/c1ccccc1)c1ccccc1OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.57
MAOB P27338 1/20 0.55
LMNA P02545 1/20 0.55
ABCB1 P08183 1/20 0.55
APP P05067 1/20 0.54
MAPT P10636 2/20 0.54
BCHE P06276 1/20 0.54
CYP2C19 P33261 1/20 0.54
SGMS2 Q8NHU3 2/20 0.54
GSK3B P49841 1/20 0.54
BACE1 P56817 1/20 0.54
PTGER1 P34995 1/20 0.52
PTGER4 P35408 1/20 0.52
PTGER3 P43115 1/20 0.52
PTGER2 P43116 1/20 0.52
SLC5A1 P13866 1/20 0.52
SLC5A2 P31639 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL658208 1.00 ABCG2 (0.57) ABCG2MAOBLMNAABCB1APP
SCHEMBL31233224 0.91 MAOA (0.63) MAOBLMNAAPPMAPTSLC5A1
SCHEMBL657272 0.91 CYSLTR1 (0.65) ABCG2MAOBAPPMAPTGSK3B
SCHEMBL30382955 0.91 MAOA (0.63) MAOBLMNAAPPMAPTSLC5A1
SCHEMBL25198653 0.91 MAOA (0.63) MAOBLMNAAPPMAPTSLC5A1
SCHEMBL25202012 0.91 MAOB (0.59) ABCG2MAOBAPPGSK3BBACE1
SCHEMBL31233096 0.91 MAOB (0.59) ABCG2MAOBAPPGSK3BBACE1
SCHEMBL25221855 0.91 MAOA (0.63) MAOBLMNAAPPMAPTSLC5A1
SCHEMBL657273 0.91 CYSLTR1 (0.65) ABCG2MAOBAPPMAPTGSK3B
SCHEMBL9577552 0.87 ALDH1A1 (0.61) LMNAMAPTSGMS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3437640-B1 AGENT FOR TREATING SYNUCLEINOPATHY UNIV TOHOKU (JP) 2021-11-24 EP disclosed
US-10709688-B2 Agent for treating synucleinopathy TOHOKU UNIVERSITY (JP) 2020-07-14 US disclosed
US-20190125726-A1 AGENT FOR TREATING SYNUCLEINOPATHY TOHOKU UNIVERSITY (JP) 2019-05-02 US disclosed
EP-3437640-A1 SYNUCLEINOPATHY THERAPEUTIC MEDICATION Tohoku University (JP) 2019-02-06 EP disclosed
EP-2349999-B1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIV SAARLAND (DE) 2016-01-27 EP disclosed
US-8912186-B2 Allosteric protein kinase modulators UNIVERSITAET DES SAARLANDES (DE) 2014-12-16 US disclosed
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2012-02-23 US disclosed
EP-2349999-A1 ALLOSTERIC PROTEIN KINASE MODULATORS Universität des Saarlandes (DE) 2011-08-03 EP disclosed
WO-2010043711-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2010-04-22 WO disclosed
EP-2177510-A1 Allosteric protein kinase modulators Universität des Saarlandes (DE) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10709688-B2 Agent for treating synucleinopathy SNCA, PARK7, SYNJ1 ABCG2 3730/4885MAOB 1106/4885LMNA 2568/4885
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS AURKC, AURKA, AURKB ABCG2 735/4885MAOB 4512/4885LMNA 3119/4885
US-20190125726-A1 AGENT FOR TREATING SYNUCLEINOPATHY SNCA, PARK7, SYNJ1 ABCG2 3730/4885MAOB 1106/4885LMNA 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.